Document |
Document Title |
WO/2024/035545A1 |
Provided are methods for: removing cardiac cells impaired or functionally diminished by stress or age, wherein optionally cardiac cells impaired or functionally diminished have reduced proliferative capacity and/or polyploidy, initiating...
|
WO/2024/033459A1 |
The present invention relates to pharmaceutical compositions comprising 5-ethyl-4- methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.
|
WO/2024/031997A1 |
The present invention relates to N-N-bis-oxazolidinone alkaloid compounds, a preparation method and a use in the medical field. The present invention provides two new N-N-bis-oxazolidinone alkaloid isomers isolated and purified from Loni...
|
WO/2024/035035A1 |
The present invention relates to a pharmaceutical composition for preventing or treating a degenerative valvular disease such as aortic stenosis, and has been completed by confirming that, when protein-arginine deiminase (PAD) proteins a...
|
WO/2024/028192A1 |
The present invention relates to CRP-binding phosphocholine-HSA conjugates and their use for binding and/or neutralizing CRP in the blood flow. The phosphocholine-HSA conjugates according to the invention are specifically useful in the t...
|
WO/2024/028782A1 |
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relat...
|
WO/2024/027694A1 |
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...
|
WO/2024/031016A1 |
Methods for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) an...
|
WO/2024/027809A1 |
The present invention pertains to the field of biopharmaceutics, and particularly relates to an RNA inhibitor for inhibiting APOC3 gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor comprises a sense strand ...
|
WO/2024/027641A1 |
An IRAK4 inhibitor composition, a preparation method therefor and use thereof. The composition comprises: (i) a compound of formula I, a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof; (ii) a diluent; (iii) a disin...
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
WO/2024/027593A1 |
The present invention relates to use of a Jun inhibitor in preparing a medicament for treating heart failure with preserved ejection fraction (HFpEF).
|
WO/2024/027521A1 |
Provided are a methylophiopogonone A derivative, and the preparation and the use thereof. The present invention specifically relates to three derivatives of methylophiopogonone A, which derivatives have the chemical structures of formula...
|
WO/2024/030080A1 |
The present invention generally relates to recombinant polypeptides capable of regulating actin remodelling. In particular, the polypeptides disclosed herein are selective for ADP-actin and may modulate ADP-actin remodelling under energy...
|
WO/2024/027779A1 |
Provided are a new crystal form of an ARNi compound, a preparation method therefor, and use thereof.
|
WO/2024/027116A1 |
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...
|
WO/2024/027750A1 |
Provided herein are methods of treating pulmonary hypertension, particularly pulmonary arterial hypertension (PAH) pulmonary arterial hypertension in a subject, comprising administering to the subject in need thereof a BTK inhibitor, or ...
|
WO/2024/030615A1 |
The disclosure provides methods of treating hypertension in a subject in need thereof, comprising administering baxdrostat.
|
WO/2024/029599A1 |
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methox
yphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolid
ine-3-yl]-5-(trifluoromethyl)phenyl}p...
|
WO/2024/026058A1 |
The present invention provides crystalline forms of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2
H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(
1H,3H)-dione ("Compound I"). Also provided are related pharmace...
|
WO/2024/023196A1 |
The present invention relates to the use of Antithrombin in the treatment of stroke.
|
WO/2024/026290A1 |
The present invention relates to compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions of the compounds, or salts thereof, that can inhibit secreted phospholipases A2 (sPLA2-X) enzymes, wherein th...
|
WO/2024/026444A1 |
Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leuci...
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
WO/2024/025817A1 |
Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrid
o[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use t...
|
WO/2024/023369A1 |
The present application is directed to an anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment or prevention of shock in a patient, wherein said patient is characterized by...
|
WO/2023/238952A9 |
The present invention provides a pharmaceutical composition containing a pharmaceutically acceptable salt of (2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)ace
tic acid (compound B) with good storage stability. The present in...
|
WO/2024/023360A1 |
The present invention provides IP5 substituted compounds of general formula I, their methods of synthesis and their uses. The IP5 substituted compounds of the invention are characterized for having -O(alkyl)nX, and -O(alkyl)yCy(alkyl)y'-...
|
WO/2024/021024A1 |
A heart-protecting factor miR-139-3p and use thereof. Provided is use of miR-139-3p in the preparation of a formulation for regulating and controlling macrophage polarization. Also provided are use of a reagent material that overexpresse...
|
WO/2024/022481A1 |
The present invention belongs to the technical field of medicines. Disclosed are phenyl-substituted dihydronaphthyridine compounds and preparation and use thereof. The compound disclosed by the present invention is represented by formula...
|
WO/2024/022382A1 |
An osmotic pump controlled release preparation, which comprises the following structures sequentially arranged from inside out: a tablet core containing a drug-containing layer and a push layer, a controlled-release coating layer having ...
|
WO/2024/021429A1 |
The present invention belongs to the field of biotechnology, and particularly relates to a gene delivery system targeting retina and use thereof. The gene delivery system targeting retina comprises an adeno-associated virus vector rAAV11...
|
WO/2024/025953A2 |
Disclosed are methods for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, or cancer. Also disclosed is a method of enhancing cancer immunotherapy.
|
WO/2024/023710A1 |
The present invention provides a pharmaceutical composition which is a tablet comprising tafamidis free acid, one or more diluents, 7-9% (w/w%) disintegrant and a lubricant. A representative example is a tablet comprising about 11.6% (w/...
|
WO/2024/023312A1 |
There is provided inter alia a pharmaceutical formulation comprising a catechin component for use in the treatment or prevention of diabetic cardiomyopathy.
|
WO/2024/023068A1 |
The present invention concerns the use of a molecule chosen from a globin, a globin protomer or an extracellular hemoglobin of Annelids, for treating and/or preventing at least one complement-activation associated disease, preferably isc...
|
WO/2024/023295A1 |
The application relates to a pharmaceutical composition comprising Imatinib and a stabilizing formulation, wherein said stabilizing formulation comprises a bulking agent and a buffering agent, wherein the pH of the pharmaceutical composi...
|
WO/2024/020468A1 |
Methods for treating non-obstructive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with mid- ventricular obstruction (MVO) are described herein. The treatment methods include the administration of a cardiac myosin inhibitor ...
|
WO/2024/019171A1 |
The purpose of the present invention is to provide a composition that improves conditions related to ocular blood flow by evaluating effects on ocular blood flow. Provided is a composition for improving and/or maintaining ocular blood fl...
|
WO/2024/019080A1 |
The present invention provides: a method for producing umbilical cord-derived mesenchymal cells that highly express a vascular endothelial growth factor, the method comprising a step for culturing an umbilical cord-derived mesenchymal st...
|
WO/2024/017331A1 |
The present invention belongs to the fields of bioengineering and biological treatment. Disclosed are an anti-ADM monoclonal antibody or a fragment thereof and a pharmaceutical composition, a detection reagent, or a kit comprising the mo...
|
WO/2024/017423A1 |
The invention relates to a peptide identified as SEQ ID NO: 1, for use in the manufacture of a medicine for the treatment of a disease associated with apolipoprotein A-l (Apo-Al) or transthyretin (TTR) involvement. In particular, the pep...
|
WO/2024/016935A1 |
The present invention belongs to the field of functional emulsions. Disclosed is a method for improving the embedding rates of ginsenosides Rg3 and CK and the stability of a nanoemulsion. The method for improving the embedding rates of r...
|
WO/2024/019661A1 |
The present disclosure concerns a method of promoting the ubiquitination of MK2 protein, comprising contacting the MK2 protein with a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof. The present disclosure als...
|
WO/2024/019509A1 |
The present invention provides a pharmaceutical composition for preventing or treating metabolic diseases comprising a novel pan-PPAR agonist compound or a salt thereof as an active ingredient. As a pan-PPAR agonist, the compound or the ...
|
WO/2024/017144A1 |
Provied are a class of substituted imidazo[1,2-a]pyridine compounds, pharmaceutical compositions containing the same, and use of the compounds in the treatment and prevention of fibrosis.
|
WO/2024/017915A1 |
The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine ...
|
WO/2024/017257A1 |
The present application relates to an aromatic substituent-containing heteroaryl- or phenyl-imidazole compound, and a stereoisomer, hydrate, solvate, pharmaceutically-acceptable salt or prodrug thereof. The present application also relat...
|
WO/2024/017366A1 |
Provided are a compound of formula (I) having an effect of regulating and controlling the activity of 15-PGDH, a stereoisomer, a tautomer or a form of a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof...
|
WO/2024/018440A1 |
Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA...
|